# Summaries for patients. Exenatide therapy for type 2 diabetes.

> PubMed lists PMID 17404346 in Annals of internal medicine as Journal Article, Patient Education Handout, with publication-date metadata of 2007-04-03 (day precision). PeptideScanner associated the retained record with the identity slug exenatide. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.

- Evidence object: `story:pubmed-pmid-17404346-exenatide:v1`
- Evidence domain: Literature metadata
- Date in source: 2026-01-28
- Source checked: 2026-07-30
- Published by PeptideScanner: 2026-08-13
- Story landing page: https://peptidescanner.com/stories/pubmed-pmid-17404346-exenatide/
- JSON record: https://peptidescanner.com/evidence/v1/objects/pubmed-pmid-17404346-exenatide-v1.json
- Content SHA-256: `7dd6292eb574fe16369564f3ce4c263cabb7d12442734b7bec9a0370f4b29f10`

## Claims and source pins

### Headline

Summaries for patients. Exenatide therapy for type 2 diabetes. ([`pubmed-observation-pmid-17404346-2026-01-28-cafd6188ea6e`](#source-pubmed-observation-pmid-17404346-2026-01-28-cafd6188ea6e))

### Summary

PubMed lists PMID 17404346 in Annals of internal medicine as Journal Article, Patient Education Handout, with publication-date metadata of 2007-04-03 (day precision). PeptideScanner associated the retained record with the identity slug exenatide. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings. ([`pubmed-observation-pmid-17404346-2026-01-28-cafd6188ea6e`](#source-pubmed-observation-pmid-17404346-2026-01-28-cafd6188ea6e))

### Paragraph 1

PubMed lists PMID 17404346 in Annals of internal medicine as Journal Article, Patient Education Handout, with publication-date metadata of 2007-04-03 (day precision). PeptideScanner associated the retained record with the identity slug exenatide. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings. ([`pubmed-observation-pmid-17404346-2026-01-28-cafd6188ea6e`](#source-pubmed-observation-pmid-17404346-2026-01-28-cafd6188ea6e))

### Paragraph 2

This page reproduces bounded bibliographic metadata attributed to PubMed. Its title and publication details are source metadata, not PeptideScanner's endorsement or an assertion of safety, efficacy, or scientific truth. ([`pubmed-observation-pmid-17404346-2026-01-28-cafd6188ea6e`](#source-pubmed-observation-pmid-17404346-2026-01-28-cafd6188ea6e))

## Sources

<a id="source-pubmed-observation-pmid-17404346-2026-01-28-cafd6188ea6e"></a>
- **Summaries for patients. Exenatide therapy for type 2 diabetes. · retained source version 1:2026-01-28:current:cafd6188ea6e31e5e24be5083ddd428cbf8512bb747aad863da81df1d22ae551** — PubMed; class A. [Open source](https://pubmed.ncbi.nlm.nih.gov/17404346/) (`pubmed-observation-pmid-17404346-2026-01-28-cafd6188ea6e`)

## Correction lineage

No correction is recorded for this version.

## Reporting boundaries and unknowns

PeptideScanner reproduces bounded bibliographic metadata attributed to PubMed. It does not summarize or endorse the article's findings.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

## Suggested citation

PeptideScanner. "Summaries for patients. Exenatide therapy for type 2 diabetes." Version 1, published 2026-08-13. https://peptidescanner.com/evidence/v1/objects/pubmed-pmid-17404346-exenatide-v1.json SHA-256: 7dd6292eb574fe16369564f3ce4c263cabb7d12442734b7bec9a0370f4b29f10.